Reduced low-affinity anti-β-amyloid autoantibodies in serum from Alzheimer's disease
-
摘要:
目的研究AD病人血清中Aβ自身抗体的特性及对老年斑的亲和力。 方法选择AD、血管性痴呆（vascular dementia, VD）患者及正常老年人做为研究对象，采集血清标本，测定抗体含量，并亲和纯化抗体进行免疫组化染色。 结果AD患者血清中含有低水平的Aβ自身抗体，但抗体含量与性别、年龄和MMSE评分没有相关性；AD体内的抗体不能识别Tg2576鼠脑内的老年斑。 结论Aβ自身抗体的降低是AD病人特有的免疫低反应性所致；Aβ自身抗体与老年斑的亲和力明显降低；这些抗体的病理生理作用需要进一步研究。 Abstract:ObjectiveTo investigate the characterization of anti-Aβ autoantibodies in AD patients and affinity ability of autoantibodies stainning the Aβplaques in vitro. MethodsELISA was performed to detect levels of naturally occuring anti-Aβautoantibodies in surum from AD patients, vascular dementia and age-macthed healthy controls. Immunohistochemistry assay was employed to confirm the affinity abillity of anti-Aβautoantibodies stainning the Aβ plaques in vitro. ResultsNaturally occuring anti-Aβautoantibodies in surum from AD patients was significantly lower than those from vascular dementia and healthy controls. The autiantibodies levels were independent of gender, age and MMSE scores in AD patients. Autoantibodies purified from healthy individuals and vascular dementia patients could readily stain the Aβplaques in transgenic mouse Tg2576, while those from AD patients could not. ConclusionCompared with vascular dementia and healthy controls, AD patients have obviously lower anti-Aβautoantibodies which could not stain Aβplaques in transgenic mouse and showed a low-affinity ability with Aβplaques in vitro. The petential pathophysiological function of autoantibodies in AD patients needs futher study. -
Key words:
- Alzheimer's disease /
- Vascular dementia /
- anti-Aβ autoantibody
-
表 1 研究对象临床特征简表(Mean±SD)
组别 例数 年龄(岁) 性别(男/女) MMSE (范围) AD 60 65. 22±8.58 (60~80) 22/38 13±4.51(8~22) VD 30 63±7.86(58~78) 12/18 12±5.49(10~22) HC 30 64.35±9.15 (60~80) 14/16 29±1(28~30) 
下载: 导出CSV
-
[1] Shayan G1, Adamiak B, Choe LH, et al. Longitudinal effects of intravenous immunoglobulin on Alzheimer's cerebrospinal fluid proteome[J]. Electrophoresis, 2014, 22: 13-4. https://www.ncbi.nlm.nih.gov/pubmed/24756957 [2] Xu S, Gaskin F.Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease[J]. Mech Ageing Dev, 1997, 94(1/3): 213-22. https://www.ncbi.nlm.nih.gov/pubmed/9147373 [3] Hyman BT, Smith C, Buldyrev I, et al. Autoantibodies to amyloid-beta and Alzheimer's disease[J]. Ann Neurol, 2001, 49(6): 808-10. doi: 10.1002/(ISSN)1531-8249 [4] Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease[J]. Nature, 2001, 408(6815): 982-5. https://www.ncbi.nlm.nih.gov/pubmed/11140686 [5] Check E. Nerve inflammation halts trial for Alzheimer's drug[J]. Nature, 2002, 415(6871): 462. http://www.nature.com/nature/journal/v415/n6871/full/415462a.html [6] Ferrer I, Boada Rovira M, Sánchez Guerra ML, et al. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease[J]. Brain Pathol, 2004, 14(1): 11-20. doi: 10.1111/j.1750-3639.2004.tb00493.x [7] 金伯泉.细胞和分子免疫学实验技术[M].第四军医大学出版社, 2002: 18-9. [8] 李少兵, 汪华侨, 林贤, 等.接种Aβ_(42)全肽疫苗恒河猴的特异性体液免疫应答[J].细胞与分子免疫学杂志, 2005, 21(2): 202-4. http://mall.cnki.net/magazine/article/XBFM20050200L.htm [9] 段金海, 徐书雯, 莫建伟, 等. Alzheimer患者血清中抗Aβ42自身抗体的纯化及鉴定[J].细胞与分子免疫学杂志, 2009, 25(1): 53-4, 57. http://www.cnki.com.cn/Article/CJFDTOTAL-XBFM200901016.htm [10] 段金海, 徐书雯, 莫建伟, 等.人抗Aβ42自身抗体的纯化及鉴定[J].解剖学研究, 2011, 33(3): 172-5. http://www.cnki.com.cn/Article/CJFDTOTAL-GDJP201103005.htm [11] Selkoe DJ. Clearing the brain's amyloid cobwebs[J]. Neuron, 2001, 32(2): 177-80. doi: 10.1016/S0896-6273(01)00475-5 [12] Monsonego A, Maron R, Zota V, et al. Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice:implications for the pathogenesis and treatment of Alzheimer's disease[J]. Proc Natl Acad Sci USA, 2001, 98(18): 10273-8. doi: 10.1073/pnas.191118298 [13] Trieb K, Ransmayr G, Sgonc R, et al. APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease[J]. Neurobiol Aging, 1996, 17(4): 541-7. doi: 10.1016/0197-4580(96)00068-1 [14] Du Y, Dodel R, Hampel H, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease[J]. Neurology, 2013, 57(5): 801-5. https://www.ncbi.nlm.nih.gov/pubmed/11552007 [15] 杨志勇, 汪华侨, 张革, 等.国人外周血抗β-淀粉样蛋白抗体水平的依龄性变化[J].中山大学学报:医学科学版, 2005, 26(2): 125-8. http://www.cnki.com.cn/Article/CJFDTotal-ZSYK200502003.htm [16] Di Luca M, Colciaghi F, Pastorino L, et al. Platelets as a peripheral district where to study pathogenetic mechanisms of alzheimer disease: the case of amyloid precursor protein[J]. Eur J Pharmacol, 2000, 405(1/3): 277-83. https://www.ncbi.nlm.nih.gov/pubmed/11033334 [17] 马晋, 段金海, 邹俊涛, 等.人源化抗Aβ抗体治疗APP/PS1转基因鼠的实验研究[J].新医学, 2014, 45(2): 95-8. http://www.cnki.com.cn/Article/CJFDTOTAL-XYXX201402006.htm [18] Mclaurin J, Cecal R, Kierstead ME, et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis[J]. Nat Med, 2002, 8(11): 1263-9. doi: 10.1038/nm790 [19] Demattos RB, Bales KR, Cummins DJ, et al. Brain to plasma amyloid-beta efflux:a measure of brain amyloid burden in a mouse model of Alzheimer's disease[J]. Science, 2002, 295(5563): 2264-7. doi: 10.1126/science.1067568 -
点击查看大图
图(1) / 表(1)
计量
- 文章访问数: 496
- HTML全文浏览量: 231
- PDF下载量: 3
- 被引次数: 0
